907582 Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 2/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Amgen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$226.36 |
| 52 Week High | US$240.08 |
| 52 Week Low | US$198.51 |
| Beta | 0.58 |
| 1 Month Change | 0% |
| 3 Month Change | -0.51% |
| 1 Year Change | n/a |
| 3 Year Change | 25.87% |
| 5 Year Change | 11.40% |
| Change since IPO | 186.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 907582 | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | -2.1% |
| 1Y | n/a | 15.8% | -3.6% |
Return vs Industry: Insufficient data to determine how 000907582 performed against the Swiss Biotechs industry.
Return vs Market: Insufficient data to determine how 000907582 performed against the Swiss Market.
Price Volatility
| 907582 volatility | |
|---|---|
| 907582 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: 000907582 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 000907582's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 25,200 | Bob Bradway | www.amgen.com |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Amgen Inc. Fundamentals Summary
| 907582 fundamental statistics | |
|---|---|
| Market cap | CHF126.76b |
| Earnings (TTM) | CHF6.58b |
| Revenue (TTM) | CHF23.33b |
19.3x
P/E Ratio5.4x
P/S RatioIs 907582 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 907582 income statement (TTM) | |
|---|---|
| Revenue | US$26.83b |
| Cost of Revenue | US$7.05b |
| Gross Profit | US$19.78b |
| Other Expenses | US$12.22b |
| Earnings | US$7.57b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.14 |
| Gross Margin | 73.73% |
| Net Profit Margin | 28.20% |
| Debt/Equity Ratio | 789.8% |
How did 907582 perform over the long term?
See historical performance and comparison